The firm will use the financing to commercialize a test that utilizes metabolomic and DNA biomarkers to characterize obesity and guide weight loss.
A tick-borne disease working group recommends the federal government explore using new technologies and repurposing existing ones to improve diagnosis.
A new study suggests binding proteins that target glucose or asparagine can be used in combination with cytolysin A-based nanopores to electrically detect the metabolites.
The handheld device uses CMOS technology for multiplexed measurement of disease-linked metabolites and could prove useful for inexpensive POC testing.
The grants include funding for five new clinical sites, a new metabolomics core, and increased model organism capabilities.
The company published data from a 1,102-patient trial that found that amino acid markers could be useful for diagnosing the condition in a subset of patients.
The biomarker profiling project is expected to enable a better understanding of how lifestyle, environment, and genetics combine to cause diseases.
The company is now commencing a trial of the test platform in 250 patients to generate more data while it considers how to best commercialize it.
With European Union funds, the firm is accelerating its go-to-market strategy for the PrePsia four-metabolite, mass spec-based blood test for preterm preeclampsia.
The firms are collaborating to develop a solution that includes Nightingale's nuclear magnetic resonance assay and PerkinElmer's sequencing services.